A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers

American Journal of Tropical Medicine and Hygiene

Volumn 81, Issue 2, 2009, Pages 356-362

  Leary, Kevin J ^a,b   Riel, Michael A ^b   Roy, Michael J ^b   Cantilena, Louis R ^b   Bi, Daoqin ^b   Brater, D Craig ^c   Van De Pol, Corina ^d   Pruett, Khadeeja ^e   Kerr, Caron ^e   Veazey Jr , James M ^a   Beboso, Ronnie ^f   Ohrt, Colin ^g  

^a U S ARMY   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c INDIANA UNIVERSITY   (United States)

^d Acufocus Inc   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HAPTOGLOBIN; HEMOGLOBIN; PLACEBO; TAFENOQUINE;

ADULT; ARTICLE; BACKACHE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA DISEASE; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; EYE TOXICITY; FALLING; FATIGUE; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; HEADACHE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION; LIMB FRACTURE; LOADING DRUG DOSE; MALE; MEASUREMENT; NAUSEA; NEPHROTOXICITY; NIGHT VISION; NORMAL HUMAN; NOSE CONGESTION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; RHINOPHARYNGITIS; SIDE EFFECT; SORE THROAT; URINARY TRACT INFECTION; VISION; VISUAL FIELD DEFECT;

EID: 68549115281     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2009.81.356     Document Type: Article

References (24)

1. Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97-106. (Pubitemid 32552576)
2. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM, 2007. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 79-87.
3. Baird JK, 2005. Effectiveness of antimalarial drugs. N Engl J Med 352: 1565-1577.
4. Crockett M, Kain KC, 2007. Tafenoquine: a promising new antimalarial agent. Expert Opin Investig Drugs 16: 705-715. (Pubitemid 46723273)
5. Peters W, 1999. The evolution of tafenoquine-antimalarial for a new millennium? J R Soc Med 92: 345-352.
6. World Health Organization, 2006. Guidelines for the Treatment of Malaria. Geneva, Switzerland, WHO. Available at: www.who.int/malaria/docs/ TreatmentGuidelines2006.pdf. Accessed September 4, 2007.
7. Walsh DS, Eamsila C, Sasiprapha T, Sangkharomya S, Khaewsathien P, Supakalin P, Tang DB, Jarasrumgsichol P, Cherdchu C, Edstein MD, Rieckmann KH, Brewer TG, 2004. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. J Infect Dis 190: 1456-1463.
8. Walsh DS, Looareesuwan S, Wilairatana P, Heppner DG Jr, Tang DB, Brewer TG, Chokejindachai W, Viriyavejakul P, Kyle DE, Milhous WK, Schuster BG, Horton J, Braitman DJ, Brueckner RP, 1999. Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis 180: 1282-1287. (Pubitemid 30070215)
9. Melinda Gates Foundation, 2007. Eradication of Malaria. Available at: http://www.gatesfoundation.org/MediaCenter/Speeches/Co-ChairSpeeches/ BillgSpeeches/BGSpeechMalariaForum-071017.htm. Accessed November 2007.
10. Nasveld P, Edstein M, Brennan L, 2008. Randomized, double-blind study of the safety, tolerability and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in non-immune subjects. Clin Infect Dis (submitted).
11. Barbur J, Harlow A, 1993. Colour vision testing using spatiotemporal luminance masking: psychophysical and pupillometric methods. Drum B, ed. Colour vision deficiencies XI. Proceedings of the Eleventh Symposium of the International Research Group on Colour Vision Deficiencies, Sydney, Australia, June 21-23, 1991. Dordrecht: Kluwer Academic Publishers, 417-426.
12. Bi D, Leary KJ, Weitz JA, Cherstniakova SA, Reil MA, Roy MJ, Cantilena LR, 2007. High performance liquid chromatographic measurement of iothalamate in human serum and urine for evaluation of glomerular filtration rate. J Chromatogr B Analyt Technol Biomed Life Sci 856: 95-99. (Pubitemid 47302915)
13. Dowling TC, Frye RF, Fraley DS, Matzke GR, 1999. Comparison of iothalamate clearance methods for measuring GFR. Pharmacotherapy 19: 943-950. (Pubitemid 29377312)
14. Gaspari F, Mosconi L, Vigano G, Perico N, Torre L, Virotta G, Bertocchi C, Remuzzi G, Ruggenenti P, 1992. Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. Kidney Int 41: 1081-1084.
15. Clopper C, Pearson E, 1934. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26: 404-413.
16. Anderson N, Borlak J, 2006. Drug-induced phospholipidosis. FEBS Lett 580: 5533-5540.
17. Jones SK, 1999. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 140: 3-7.
18. Lullmann H, Lullmann-Rauch R, Wassermann O, 1975. Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol 4: 185-218.
19. Brater DC, 2002. Measurement of renal function during drug development. Br J Clin Pharmacol 54: 87-95. (Pubitemid 36124761)
20. Kemperman FA, Surachno J, Krediet RT, Arisz L, 2002. Cimetidine improves prediction of the glomerular filtration rate by the Cockcroft-Gault formula in renal transplant recipients. Transplantation 73: 770-774. (Pubitemid 34260576)
21. Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL, 2003. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis 36: 541-549. (Pubitemid 36259557)
22. Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, Kremsner PG, 2000. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet 355: 2041-2045. (Pubitemid 30339243)
23. Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R, 2001. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 33: 1968-1974. (Pubitemid 33152389)
24. Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S, 2004. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 59: 1095-1103. (Pubitemid 40169305)